

### Remarks

Applicants request entry of the amendments to the specification and to the claims without prejudice to place the application in conformance with US Patent practice and to facilitate prosecution of the present application. Applicants submit that the proposed amendments are fully supported by the original application.

The amendments to Claim 3 at the X substituent deletes original S(O) and N, leaving single bond, O, and S. Applicants submit that support for the amendment can be found in the examples having X as a bond, preferred features of the invention as set forth on page 24, and Claims 9 and 10.

The amendments to Claim 3 at the Y substituent are supported by original Claims 11-13, and pursuant to Article 34 (b) amendments made during prosecution during the PCT prosecution stage of the present application.

The amendments to the structure of Claim 3 are supported by the Examples and by Claim 8 as originally filed.

The Claim 3 definition for E is amended to remove the possibility for E to be "A". Additionally, when E is C(R3)(R4)A, A is carboxyl. Applicants maintain that support for this limitation is found in original Claim 16, and preferred features of the invention on page 24 of the specification.

R3 and R4 have each been limited. R3 to lower alkyl and R4 to methyl. Applicants submit that support for this amendment is provided by the list of preferred embodiments in the specification on page 24, and the majority of the examples have this feature.

Applicants hereby reserve the right to file one or more continuation applications to claim withdrawn or canceled subject matter.

Applicants respectfully request entry of the amendments and prompt favorable consideration.

Respectfully submitted,



MaCharri Vorndran-Jones

Attorney for Applicants

Registration No. 36,711

Phone: 317-276-1665

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

18 May 2006